SLCO1B1基因多态性与高脂血症患者服用他汀类药物疗效的相关性  

Correlation between SLCO1B1 gene polymorphism and statin efficacy in patients with hyperlipidemia

作　　者：才奇博 丁琦 郭家鼎 任占军 杜欣 李亚东 张智龙 Cai Qibo;Ding Qi;Guo Jiading;Ren Zhanjun;Du Xin;Li Yadong;Zhang Zhilong(Department of Clinical Laboratory,the Third Affiliated Hospital of Qiqihar Medical College,Qiqihar 161000,Heilongjiang,China)

机构地区：[1]齐齐哈尔医学院附属第三医院检验科,黑龙江省齐齐哈尔161000

出　　处：《实用检验医师杂志》2024年第4期350-353,共4页Chinese Journal of Clinical Pathologist

基　　金：黑龙江省齐齐哈尔市科技攻关项目(LSFGG-2024027)。

摘　　要：目的分析溶质载体有机阴离子转运蛋白家族成员1B1(SLCO1B1)基因多态性与黑龙江省齐齐哈尔地区高脂血症患者服用他汀类药物疗效的相关性。方法选择齐齐哈尔医学院附属第三医院2024年1—6月住院治疗的100例血脂异常或服用他汀类药物患者作为研究对象。提取所有患者的基因组DNA,采用PCR-荧光探针法检测SLCO1B1基因多态性,统计并比较等位基因频率及基因型频率。根据他汀类药物的治疗效果将患者分为疗效不良组(18例)、疗效正常组(69例)、疗效良好组(13例),统计并比较各组的SLCO1B1基因型分布。结果SLCO1B1基因型频率分布:*1b/*1b型、*1a/*1b型、*1b/*15型、*1a/*1a型、*1a/*15型、*15/*15型的基因型频率分别为43.0%、30.0%、16.0%、6.0%、3.0%、2.0%,而*1a/*5型、*5/*5型、*5/*15型的基因型频率均为0%。疗效不良组、疗效正常组、疗效良好组的基因型分布比较差异无统计学意义,整体分布均匀,正常风险基因型*1b的等位基因频率最高(为65.0%),其次为中度风险基因型*1a(等位基因频率为23.5%),高度风险基因型*15的等位基因频率最低(为11.5%)。结论齐齐哈尔地区高脂血症患者适合选用他汀类药物治疗,利用基因型别对给药频率和剂量进行调整,能保证临床疗效,减少不良反应。Objective To analyze the correlation between the polymorphism of solute carrier organic anion transporter family member 1B1(SLCO1B1)gene and the therapeutic effect of statin therapy in patients with hyperlipidemia in Qiqihar area,Heilongjiang Province.Methods The 100 patients with dyslipidemia or taking statins in the Third Affiliated Hospital of Qiqihar Medical College from January to June 2024 were selected as study objects.Genomic DNA was extracted from all patients,and the SLCO1B1 gene polymorphism was determined using PCR-fluorescence probe method,and the allele frequency and genotype frequency were statistically compared.According to the therapeutic effect of statins,the patients were divided into poor efficacy group(18 cases),normal efficacy group(69 cases)and good efficacy group(13 cases).The genotype frequency distribution of SLCO1B1 among all groups was statistically and compared.Results SLCO1B1 genotype frequency distribution:the genotype frequencies of type*1b/*1b,type*1a/*1b,type*1b/*15,type*1a/*1a,type*1a/*15 and type*15/*15 were 43.0%,30.0%,16.0%,6.0%,3.0%and 2.0%.The genotype frequencies of type*1a/*5,type*5/*5 and type*5/*15 were all 0%.There was no statistical significance in the difference of genotype distribution in poor efficacy group,normal efficacy group and good efficacy group,and the overall distribution was uniform.The normal risk genotype*1b had the highest allele frequency(65.0%),followed by the moderate risk genotype*1a(allele frequency was 23.5%),and the high-risk genotype*15 had the lowest allele frequency(11.5%).Conclusions The patients with hyperlipidemia in Qiqihar area are suitable for statin therapy.By adjusting the frequency and dosage of medication based on genotype,clinical efficacy could be ensured and adverse reactions could be reduced.

关 键 词：有机阴离子转运蛋白家族成员1B1 基因多态性 高脂血症 他汀 基因频率 

分 类 号：R96[医药卫生—药理学]